MedTrace Logo

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer

NCT04002479 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2025-12-02

No results posted yet for this study

Summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer.

Conditions

Interventions

DEVICE

Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.

Sponsors & Collaborators

  • Alpha Tau Medical LTD.

    lead INDUSTRY

Principal Investigators

  • David Donath, MD · Brachytherapy Service Centre Hospitalier de l'Université de Montreal

  • Corey Miller, MD · Division of Gastroenterology, Jewish General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04002479 on ClinicalTrials.gov